Table 1 Patient clinical characteristics.

From: Healthy tissue metabolism assessed by [18F]FDG PET/CT as a marker of prognosis and adverse events in advanced Hodgkin lymphoma patients

Characteristics

All patients N (%)

Number of patients

198

Age (years), median (IQR)

37 (26–55)

Male sex

106 (53.5)

ECOG performance status

 0

136 (68.7)

 1

51 (25.8)

 2

9 (4.6)

 3

2 (1.0)

Ann Arbor stage

 II

88 (44.4)

 III

53 (26.8)

 IV

57 (28.8)

B symptoms

147 (74.2)

Bulky disease

69 (34.9)

International Prognostic Score

 ≤ 2

100 (50.5)

 > 2

98 (49.5)

Treatment

 ABVD

75 (37.9)

 AVD

75 (37.9)

 BEACOPP

46 (23.2)

 PET2 + , withdrawn1

2 (1.0)

Bone marrow involvement*

60 (30.3)

Spleen involvement*

131 (66.2)

Baseline MTV volume (ml), median (IQR)

174.4 (66.9–365.93)

  1. 1Withdrew post PET2 and further treatment unknown, *Bone marrow and spleen involvement based on [18F]FDG-PET/CT findings. N (%) number of patients and percentages unless indicated within brackets, ECOG Eastern Cooperative Oncology Group, IQR Interquartile range, ABVD doxorubicin, bleomycin, vinblastine, dacarbazine, AVD doxorubicin, vinblastine, dacarbazine, BEACOPP bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone.
Back to article page